试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-05
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
编号:NCT04889040登记状态:提前终止企业 / 申办者:Hoffmann-La Roche
药物 / 成分:RO7496998、Placebo
登记的停止原因(原文):Based on program revaluation and in agreement with the co-development partner the sponsor took the decision to terminate this study.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-05
A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer
编号:NCT04999605登记状态:提前终止企业 / 申办者:Akeso
药物 / 成分:AK112 low dose、AK112 medium dose、AK112 high dose
登记的停止原因(原文):Too low inclusion rate
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-03
Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH
编号:NCT00439946登记状态:提前终止企业 / 申办者:United Therapeutics
药物 / 成分:treprostinil、Crono Five ambulatory pump
登记的停止原因(原文):Study closed due to limited availability of eligible subjects and competition by for enrollment by other studies
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-03
Rapid Switch From Flolan to Remodulin in the Outpatient Clinic
编号:NCT00643604登记状态:提前终止企业 / 申办者:United Therapeutics
药物 / 成分:treprostinil sodium
登记的停止原因(原文):Due to availability of eligible subjects at center and enrollment competition with other studies.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-03
HF Assessment With BNP in the Home: Part II
编号:NCT02351063登记状态:提前终止企业 / 申办者:Alere San Diego
药物 / 成分:Changes of heart failure medications
登记的停止原因(原文):Sponsor's discretion to terminate study prematurely for further evaluation.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-03
Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi
编号:NCT02499172登记状态:提前终止企业 / 申办者:Johns Hopkins Bloomberg School of Public Health
药物 / 成分:Shanchol
登记的停止原因(原文):Financial reason
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-03
Procollagen-3 Driven Corticosteroids for Persistent Acute Respiratory Distress Syndrome
编号:NCT03371498登记状态:提前终止企业 / 申办者:Assistance Publique Hopitaux De Marseille
药物 / 成分:Methylprednisolone、Methylprednisolone placebo
登记的停止原因(原文):Insufficient recruitment of eligible patients.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-03
Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
编号:NCT03864419登记状态:提前终止企业 / 申办者:Fred Hutchinson Cancer Center
药物 / 成分:Rituximab and Hyaluronidase Human、Cyclophosphamide、Vincristine、Methotrexate
登记的停止原因(原文):Closed per SRC Low Accrual Policy
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-03
Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19
编号:NCT05124210登记状态:提前终止企业 / 申办者:GlaxoSmithKline
药物 / 成分:Sotrovimab
登记的停止原因(原文):Decrease in in-vitro neutralization of study drug against circulating SARS-CoV-2 variants
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-03
Adrecizumab (HAM8101) to Improve Prognosis and Outcomes in COVID-19 Trial
编号:NCT05156671登记状态:提前终止企业 / 申办者:Universitätsklinikum Hamburg-Eppendorf
药物 / 成分:Adrecizumab (HAM 8101)、Placebo
登记的停止原因(原文):Due to poor recruitment.
查看官方原始记录 ↗